Back to Browse Journals » Advances and Applications in Bioinformatics and Chemistry » Volume 1

A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells

Authors Junko H Ohyashiki, Ryoko Hamamura, Chiaki Kobayashi, Yu Zhang, Kazuma Ohyashiki

Published Date October 2008 Volume 2008:1 Pages 85—98

DOI http://dx.doi.org/10.2147/AABC.S4133

Published 30 October 2008

Junko H Ohyashiki1, Ryoko Hamamura2, Chiaki Kobayashi2, Yu Zhang2, Kazuma Ohyashiki2

1Intractable Immune System Disease Research Center, Tokyo Medical University, Tokyo, Japan; 2First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan

Abstract: There is a need to identify the regulatory gene interaction of anticancer drugs on target cancer cells. Whole genome expression profiling offers promise in this regard, but can be complicated by the challenge of identifying the genes affected by hundreds to thousands of genes that induce changes in expression. A proteasome inhibitor, bortezomib, could be a potential therapeutic agent in treating adult T-cell leukemia (ATL) patients, however, the underlying mechanism by which bortezomib induces cell death in ATL cells via gene regulatory network has not been fully elucidated. Here we show that a Bayesian statistical framework by VoyaGene® identified a secreted protein acidic and rich in cysteine (SPARC) gene, a tumor-invasiveness related gene, as a possible modulator of bortezomib-induced cell death in ATL cells. Functional analysis using RNAi experiments revealed that inhibition of the expression SPARC by siRNA enhanced the apoptotic effect of bortezomib on ATL cells in accordance with an increase of cleaved caspase 3. Targeting SPARC may help to treat ATL patients in combination with bortezomib. This work shows that a network biology approach can be used advantageously to identify the genetic interaction related to anticancer effects.

Keywords: network biology, adult T cell leukemia, bortezomib, SPARC

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely

Ohyashiki JH, Ohtsuki K, Mizoguchi I, Yoshimoto T, Katagiri S, Umezu T, Ohyashiki K

Drug Design, Development and Therapy 2014, 8:1151-1159

Published Date: 25 August 2014

Readers of this article also read:

Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer

Jia XQ, Hong Q, Cheng JY, Li JW, Wang YJ, Mo M, Shao ZM, Shen ZZ, Liu GY

OncoTargets and Therapy 2015, 8:549-555

Published Date: 3 March 2015

Ag-plasma modification enhances bone apposition around titanium dental implants: an animal study in Labrador dogs

Qiao SC, Cao HL, Zhao X, Lo HW, Zhuang LF, Gu YX, Shi JY, Liu XY, Lai HC

International Journal of Nanomedicine 2015, 10:653-664

Published Date: 14 January 2015

Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm [Corrigendum]

Tian XH, Wang ZG, Meng H, Wang YH, Feng W, Wei F, Huang ZC, Lin XN, Ren L

International Journal of Nanomedicine 2013, 8:2129-2130

Published Date: 13 June 2013

Prescribing tests must have curriculum support

Lemon TI, Shah RD

Advances in Medical Education and Practice 2013, 4:91-93

Published Date: 7 May 2013

A systemic administration of liposomal curcumin inhibits radiation pneumonitis and sensitizes lung carcinoma to radiation

Shi HS, Gao X, Li D, Zhang QW, Wang YS, Zheng Y, Cai LL, Zhong RM, Rui A, Li ZY, Zheng H, Chen XC, Chen LJ

International Journal of Nanomedicine 2012, 7:2601-2611

Published Date: 24 May 2012

Corrigendum

Kukulka M, Eisenberg C, Nudurupati S

Clinical and Experimental Gastroenterology 2011, 4:255-256

Published Date: 14 October 2011

Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease

Mannu P, Rinaldi S, Fontani V, Castagna A

Clinical Interventions in Aging 2011, 6:207-211

Published Date: 26 July 2011

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010

The cognitive impact of anticholinergics: A clinical review

Noll Campbell, Malaz Boustani, Tony Limbil, Carol Ott, et al.

Clinical Interventions in Aging 2009, 4:225-233

Published Date: 13 May 2009